IQ-AI Ltd (LON:IQAI) has made the first sale of its Imaging Biometrics (IB) software to South Korea, while its StoneChecker software has received a Medical Information Bulletin from the UK's National Institute for Health and Care Excellence (NICE).
The London main market-listed company said its distributor, Korea Computer ISG has sold a suite of Imaging Biometrics neuroradiology software to Haeundae Paik Hospital in Busan, South Korea, which will be installed in March 2019.
It added that the sale comprises IB's latest offering of IB Server (IB Neuro, IB Delta Suite, IB Diffusion and IB DCE, IB Rad Tech plug in).
IQ-AI also announced that UK's National Institute for Health and Care Excellence has issued a Medical Information Bulletin on its StoneChecker Software, having evaluated the clinical value and cost-effectiveness of the product.
The group said the StoneChecker software's regulatory approval process is continuing in the USA, with the recent and continuing threat of a government shutdown having delayed the review of the product.
However, the company added, it is in frequent contact with Food and Drug Administration, updating and amending the pending application to meet the FDA's requirements.
Meanwhile, IQ-AI said it continues to seek business development relationships that will expose its products to a broader audience worldwide.
It added that several marketing and distribution alliances are under active consideration with these to be evaluated, and if appropriate, will be announced in the next few months.